• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form FWP filed by Celcuity Inc.

    6/4/26 6:17:09 AM ET
    $CELC
    Medical Specialities
    Health Care
    Get the next $CELC alert in real time by email
    FWP 1 formfwp.htm FWP

     

     

    Filed Pursuant to Rule 433

    Registration No. 333-292646

    Issuer Free Writing Prospectus, dated June 3, 2026

     

    PRICING TERM SHEET

    June 3, 2026

     

     

    Celcuity Inc.

     

    $500.0 Million Aggregate Principal Amount of 0.250% Convertible Senior Notes due 2032

     

    The information in this pricing term sheet supplements Celcuity Inc.’s (“Celcuity”) preliminary prospectus supplement, dated June 3, 2026, (the “Preliminary Prospectus Supplement”), filed pursuant to Rule 424(b) under the Securities Act of 1933, as amended (the “Securities Act”), relating to an offering of convertible senior notes (the “Convertible Notes Offering”), and the accompanying prospectus, dated January 9, 2026. This pricing term sheet supersedes the information in the Preliminary Prospectus Supplement to the extent inconsistent with the information in the Preliminary Prospectus Supplement. Terms used, but not defined, in this pricing term sheet have the respective meanings set forth in the Preliminary Prospectus Supplement. As used in this pricing term sheet, “we,” “our” and “us” refer to Celcuity. Celcuity has increased the size of the Convertible Notes Offering from $400,000,000 to $500,000,000 (or, if the underwriters of the Convertible Notes Offering fully exercise their over-allotment option, $575,000,000). The final prospectus supplement relating to the Convertible Notes Offering will reflect conforming changes relating to such increase in the size of the Convertible Notes Offering.

     

    Issuer:   Celcuity Inc.
         
    Ticker/Exchange for Our Common Stock (“Common Stock”):   “CELC” / The Nasdaq Capital Market
         
    Securities:   0.250% Convertible Senior Notes due 2032 (the “Notes”)
         
    Offering Size:   $500.0 million aggregate principal amount of Notes (or $575.0 million aggregate principal amount if the underwriters of the Convertible Notes Offering exercise their over-allotment option in full)
         
    Ranking:  

    Senior unsecured.

         
    Maturity Date:  

    August 1, 2032, unless earlier converted, redeemed or repurchased

         
    Issue Price:   100% of principal amount per Note
         
    Underwriting Discount:   3.0% of the principal amount of the Notes, and approximately $15.0 million in the aggregate (or approximately $17.3 million in the aggregate, if the underwriters of the Convertible Notes Offering exercise their over-allotment option in full)
         
    Interest:   0.250% per annum, payable semi-annually in arrears on February 1 and August 1 of each year, beginning on February 1, 2027. In addition, special interest will accrue on the Notes in the circumstances described in the Preliminary Prospectus Supplement under the caption “Description of Notes—Special Interest as Sole Remedy for Certain Reporting Defaults.”

     

     

    1

     

     

     

    Pricing Date   June 3, 2026
         
    Trade Date   June 4, 2026
         
    Settlement Date:   T+2; June 8, 2026
         
    Use of Proceeds:  

    We estimate that the net proceeds to us from the Convertible Notes Offering will be approximately $484.3 million (or approximately $557.0 million if the underwriters of the Convertible Notes Offering exercise their over-allotment option in full), after deducting the underwriting discounts and commissions and our estimated offering expenses.

     

    We intend to use the net proceeds from the Convertible Notes Offering to repay in full all outstanding obligations under its amended and restated loan agreement with Oxford Finance, LLC, as collateral agent, and the lenders party thereto and the remainder for working capital and general corporate purposes, which may include clinical trial expenditures, commercial launch expenditures, commercialization expenditures, research and development expenditures, capital expenditures, expansion of business development activities and other general corporate purposes. We may also use a portion of the proceeds for the potential acquisition of businesses, technologies, and products, although we have no current binding understandings, commitments, or agreements to do so. See “Use of Proceeds” in the Preliminary Prospectus Supplement.

         
    Last Reported Sale Price per Share of the Common Stock on June 3, 2026:   $88.95
         
    Initial Conversion Rate:   8.0302 shares of Common Stock per $1,000 principal amount of the Notes
         
    Initial Conversion Price:   Approximately $124.53 per share of Common Stock
         
    Conversion Premium:   Approximately 40.0% above the last reported sale price of our Common Stock on The Nasdaq Capital Market on June 3, 2026
         
    Joint Book-Running Managers:  

    Jefferies LLC

    J.P. Morgan Securities LLC

    TD Securities (USA) LLC

    Guggenheim Securities, LLC

         
    Lead Manager:   LifeSci Capital LLC
         
    Co-Managers:  

    Craig-Hallum Capital Group LLC

    Nomura Securities International, Inc.

    WR Securities, LLC

         
    CUSIP/ISIN:   CUSIP: 15102K AB6 / ISIN: US15102KAB61
         
    Denominations/Multiple:   $1,000 / $1,000
         
    Listing:   None

     

     

    2

     

     

     

    Increase in Conversion Rate in Connection with a Make-Whole Fundamental Change

     

    If a make-whole fundamental change occurs and the conversion date for the conversion of a Note occurs during the related make-whole fundamental change conversion period, then, subject to the provisions described in the Preliminary Prospectus Supplement under the caption “Description of Notes—Conversion Rights—Increase in Conversion Rate in Connection with a Make-Whole Fundamental Change,” the conversion rate applicable to such conversion will be increased by a number of shares of Common Stock (the “Additional Shares”) set forth in the table below corresponding (after interpolation as described below) to the make-whole fundamental change effective date and the stock price of such make-whole fundamental change:

     

    Make-Whole Fundamental

      Stock Price 
    Change Effective Date  $88.95   $110.00   $124.53   $142.50   $161.89   $200.00   $300.00   $450.00   $625.00   $825.00 
    June 8, 2026   3.2120    2.2448    1.8025    1.4066    1.1011    0.7151    0.2764    0.0796    0.0160    0.0000 
    August 1, 2026   3.2120    2.2448    1.8025    1.4066    1.1002    0.7134    0.2747    0.0786    0.0155    0.0000 
    August 1, 2027   3.2120    2.2448    1.8025    1.4011    1.0823    0.6858    0.2492    0.0646    0.0102    0.0000 
    August 1, 2028   3.2120    2.2448    1.8025    1.3665    1.0370    0.6351    0.2117    0.0471    0.0044    0.0000 
    August 1, 2029   3.2120    2.2448    1.7352    1.2813    0.9458    0.5490    0.1589    0.0267    0.0007    0.0000 
    August 1, 2030   3.2120    2.1379    1.5830    1.1168    0.7845    0.4130    0.0915    0.0076    0.0000    0.0000 
    August 1, 2031   3.2120    1.8533    1.2619    0.7979    0.4966    0.2060    0.0223    0.0000    0.0000    0.0000 
    August 1, 2032   3.2120    1.0607    0.0000    0.0000    0.0000    0.0000    0.0000    0.0000    0.0000    0.0000 

     

    If such make-whole fundamental change effective date or stock price is not set forth in the table above, then:

     

    ●if such stock price is between two stock prices in the table above or the make-whole fundamental change effective date is between two dates in the table above, then the number of additional shares will be determined by straight-line interpolation between the numbers of additional shares set forth for the higher and lower stock prices in the table above or the earlier and later dates in the table above, based on a 365- or 366-day year, as applicable; and
       
    ●if the stock price is greater than $825.00 (subject to adjustment in the same manner as the stock prices set forth in the column headings of the table above are adjusted, as described below under the caption “—Adjustment of Stock Prices and Number of Additional Shares”), or less than $88.95 (subject to adjustment in the same manner), per share of our Common Stock , then no additional shares of our Common Stock will be added to the conversion rate.

     

    Notwithstanding anything to the contrary, in no event will the conversion rate be increased to an amount that exceeds 11.2422 shares of our Common Stock per $1,000 principal amount of notes, which amount is subject to adjustment in the same manner as, and at the same time and for the same events for which, the conversion rate is required to be adjusted pursuant to the provisions described in the Preliminary Prospectus Supplement under the caption “Description of Notes—Conversion Rights—Conversion Rate Adjustments—Generally.”

     

     

     

    We have filed a registration statement (including a prospectus) and the Preliminary Prospectus Supplement with the SEC for the offering to which this communication relates. Before you invest, you should read the Preliminary Prospectus Supplement and the prospectus in that registration statement and other documents we have filed with the SEC for more complete information about us and this offering. You may get these documents free by visiting EDGAR on the SEC website at www.sec.gov. Alternatively, we, any underwriter or any dealer participating in the offering will arrange to send you the Preliminary Prospectus Supplement (or, when available, the applicable final prospectus supplement) and the accompanying prospectus upon request to: Jefferies LLC, Attn: Equity Syndicate Prospectus Department, 520 Madison Avenue, New York, NY 10022, by telephone at (877) 821-7388 or by email at prospectus_department@jefferies.com; J.P. Morgan Securities LLC, Attention Broadridge Financial Solutions, 1155 Long Island Avenue, Edgewood, New York 11717, or by email at prospectus-eq_fi@jpmchase.com and postsalemanualrequests@broadridge.com; TD Securities (USA) LLC, c/o Broadridge Financial Solutions, 1155 Long Island Avenue, Edgewood, NY 11717 or by email at TDManualrequest@broadridge.com; and Guggenheim Securities, LLC, Attention: Equity Syndicate Department, 330 Madison Avenue, New York, NY 10017, by telephone at (212) 518-9544 or by email at GSEquityProspectusDelivery@guggenheimpartners.com.

     

    The information in this pricing term sheet is not a complete description of the Notes or the Convertible Notes Offering. You should rely only on the information contained or incorporated by reference in the Preliminary Prospectus Supplement and the accompanying prospectus, as supplemented by this pricing term sheet, in making an investment decision with respect to the Notes.

     

    ANY DISCLAIMERS OR OTHER NOTICES THAT MAY APPEAR BELOW ARE NOT APPLICABLE TO THIS COMMUNICATION AND SHOULD BE DISREGARDED. SUCH DISCLAIMERS OR OTHER NOTICES WERE AUTOMATICALLY GENERATED AS A RESULT OF THIS COMMUNICATION BEING SENT VIA BLOOMBERG OR ANOTHER EMAIL SYSTEM.

     

     

    3

     

    Get the next $CELC alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $CELC

    DatePrice TargetRatingAnalyst
    5/4/2026$165.00Neutral → Buy
    H.C. Wainwright
    4/27/2026$150.00Mkt Outperform
    Citizens
    12/12/2025$126.00Overweight
    Wells Fargo
    11/18/2025$110.00Outperform
    Wolfe Research
    11/17/2025Buy → Neutral
    H.C. Wainwright
    9/22/2025$110.00Buy
    Guggenheim
    7/1/2025$30.00Buy
    Stifel
    7/22/2024$29.00Outperform
    Leerink Partners
    More analyst ratings

    $CELC
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Celcuity Inc. Announces Pricing of Upsized Public Offering of 0.250% Convertible Senior Notes Due 2032

    MINNEAPOLIS, June 03, 2026 (GLOBE NEWSWIRE) -- Celcuity Inc. (NASDAQ:CELC) ("Celcuity" or the "Company"), a clinical-stage biotechnology company focused on the development of targeted therapies for the treatment of multiple solid tumor indications, today announced the pricing of its upsized underwritten public offering of $500,000,000 aggregate principal amount of its 0.250% convertible senior notes due 2032 (the "Convertible Notes"). The aggregate principal amount of the offering was increased from the previously announced offering size of $400,000,000. The Company has granted the underwriters of the offering a 30-day option to purchase up to an additional $75,000,000 aggregate principal

    6/3/26 10:13:20 PM ET
    $CELC
    Medical Specialities
    Health Care

    Celcuity Inc. Announces Public Offering of Convertible Senior Notes Due 2032

    MINNEAPOLIS, June 03, 2026 (GLOBE NEWSWIRE) -- Celcuity Inc. (NASDAQ:CELC) ("Celcuity" or the "Company"), a clinical-stage biotechnology company focused on the development of targeted therapies for the treatment of multiple solid tumor indications, today announced a proposed underwritten public offering of $400,000,000 aggregate principal amount of its convertible senior notes due 2032 (the "Convertible Notes"). The Company intends to grant the underwriters of the offering a 30-day option to purchase up to an additional $60,000,000 aggregate principal amount of Convertible Notes, solely to cover over-allotments, if any. The Convertible Notes will be general, unsecured, senior obligations

    6/3/26 7:19:12 AM ET
    $CELC
    Medical Specialities
    Health Care

    Celcuity's Gedatolisib Combination Regimens Doubled the Likelihood of Survival without Disease Progression or Death Compared to Alpelisib plus Fulvestrant in the PIK3CA Mutant Cohort of the Pivotal Phase 3 VIKTORIA-1 Trial in Patients with HR+/HER2- Advanced Breast Cancer

    Gedatolisib plus fulvestrant and palbociclib (the "gedatolisib-triplet") reduced the risk of disease progression or death by 50% vs. alpelisib plus fulvestrant (HR=0.50; 95% CI: 0.37–0.68; p<0.0001). Median progression-free survival ("PFS") was 11.1 months with the gedatolisib triplet versus 5.6 months with alpelisib plus fulvestrantGedatolisib plus fulvestrant (the "gedatolisib-doublet") reduced the risk of disease progression or death by 49% vs. alpelisib plus fulvestrant (HR=0.51; 95% CI: 0.33–0.79; descriptive p=0.0013). Median PFS was 11.3 months with the gedatolisib-doublet versus 5.6 months with alpelisib plus fulvestrantGedatolisib regimens demonstrated robust and durable responses:

    6/2/26 8:25:57 AM ET
    $CELC
    Medical Specialities
    Health Care

    $CELC
    SEC Filings

    View All

    SEC Form FWP filed by Celcuity Inc.

    FWP - Celcuity Inc. (0001603454) (Subject)

    6/4/26 6:17:09 AM ET
    $CELC
    Medical Specialities
    Health Care

    SEC Form 424B5 filed by Celcuity Inc.

    424B5 - Celcuity Inc. (0001603454) (Filer)

    6/3/26 7:16:05 AM ET
    $CELC
    Medical Specialities
    Health Care

    Celcuity Inc. filed SEC Form 8-K: Regulation FD Disclosure

    8-K - Celcuity Inc. (0001603454) (Filer)

    6/2/26 8:10:25 AM ET
    $CELC
    Medical Specialities
    Health Care

    $CELC
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Celcuity upgraded by H.C. Wainwright with a new price target

    H.C. Wainwright upgraded Celcuity from Neutral to Buy and set a new price target of $165.00

    5/4/26 8:30:30 AM ET
    $CELC
    Medical Specialities
    Health Care

    Citizens initiated coverage on Celcuity with a new price target

    Citizens initiated coverage of Celcuity with a rating of Mkt Outperform and set a new price target of $150.00

    4/27/26 8:34:35 AM ET
    $CELC
    Medical Specialities
    Health Care

    Wells Fargo initiated coverage on Celcuity with a new price target

    Wells Fargo initiated coverage of Celcuity with a rating of Overweight and set a new price target of $126.00

    12/12/25 8:49:57 AM ET
    $CELC
    Medical Specialities
    Health Care

    $CELC
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Buller Richard E gifted 1,029 shares and received a gift of 1,029 shares, closing all direct ownership in the company (SEC Form 4)

    4 - Celcuity Inc. (0001603454) (Issuer)

    5/20/26 4:58:24 PM ET
    $CELC
    Medical Specialities
    Health Care

    Director Dalvey David sold $3,517,000 worth of shares (25,000 units at $140.68) as part of a pre-agreed trading plan (SEC Form 4)

    4 - Celcuity Inc. (0001603454) (Issuer)

    5/6/26 4:31:58 PM ET
    $CELC
    Medical Specialities
    Health Care

    Director Buller Richard E exercised 9,000 shares at a strike of $5.10 and sold $1,264,181 worth of shares (9,000 units at $140.46) as part of a pre-agreed trading plan (SEC Form 4)

    4 - Celcuity Inc. (0001603454) (Issuer)

    5/6/26 4:30:28 PM ET
    $CELC
    Medical Specialities
    Health Care

    $CELC
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Large owner Baker Bros. Advisors Lp bought $9,571,319 worth of shares (170,100 units at $56.27) (SEC Form 4)

    4 - Celcuity Inc. (0001603454) (Issuer)

    9/10/25 4:06:15 PM ET
    $CELC
    Medical Specialities
    Health Care

    $CELC
    Leadership Updates

    Live Leadership Updates

    View All

    Celcuity Appoints Charles Romp to its Board of Directors

    MINNEAPOLIS, Feb. 12, 2026 (GLOBE NEWSWIRE) -- Celcuity Inc. (NASDAQ:CELC), a clinical-stage biotechnology company pursuing development of targeted therapies for oncology, today announced the appointment of Charles (Chip) R. Romp to its Board of Directors. Mr. Romp brings over 25 years of experience in the pharmaceutical industry to Celcuity, including leadership of sales teams and commercial organizations in the oncology setting. "Chip brings a wealth of oncology-related commercial expertise to our Board," said Brian Sullivan, Chief Executive Officer and co-founder of Celcuity. "Chip's deep experience commercializing significant oncology drugs will provide valuable insight to Celcuity as

    2/12/26 4:05:00 PM ET
    $CELC
    Medical Specialities
    Health Care

    Amid NCI Budget Fears, Emerging Oncology Stocks Gain Attention

    Equity Insider News CommentaryIssued on behalf of Oncolytics Biotech Inc. VANCOUVER, BC, July 8, 2025 /PRNewswire/ -- Equity Insider News Commentary – As cancer rates climb and drug costs continue to soar, pressure is mounting on the private sector to drive innovation. Now, cancer experts are alarmed over a "gut wrenching" plan from the U.S. government to cut nearly 40% of National Cancer Institute funding, even as the price of oncology treatments pushes new limits—raising urgent concerns about access and affordability. In this shifting landscape, investors are turning their attention to a new wave of biotechs and specialty care providers developing breakthrough therapies and smarter care mo

    7/8/25 10:25:00 AM ET
    $CELC
    $CTOR
    $EXEL
    Medical Specialities
    Health Care
    Biotechnology: Pharmaceutical Preparations
    Biotechnology: Biological Products (No Diagnostic Substances)

    Celcuity Appoints Eldon Mayer as Chief Commercial Officer

    MINNEAPOLIS, Feb. 20, 2024 (GLOBE NEWSWIRE) -- Celcuity Inc. (NASDAQ:CELC), a clinical-stage biotechnology company pursuing development of targeted therapies for oncology, today announced the appointment of Eldon Mayer as Chief Commercial Officer. Mr. Mayer joins Celcuity with over 30 years of biopharmaceutical commercial experience in companies ranging from early-stage biotechs to full scale pharmaceutical companies across many therapeutic areas, including oncology. "Eldon is an exceptional leader with a proven track record of building commercial organizations from the ground up to support the launch of a biotech company's first drug. His significant commercial experience at multiple bio

    2/20/24 7:05:00 AM ET
    $CELC
    Medical Specialities
    Health Care

    $CELC
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by Celcuity Inc.

    SC 13G/A - Celcuity Inc. (0001603454) (Subject)

    11/14/24 5:46:12 PM ET
    $CELC
    Medical Specialities
    Health Care

    Amendment: SEC Form SC 13G/A filed by Celcuity Inc.

    SC 13G/A - Celcuity Inc. (0001603454) (Subject)

    11/14/24 5:46:16 PM ET
    $CELC
    Medical Specialities
    Health Care

    SEC Form SC 13G filed by Celcuity Inc.

    SC 13G - Celcuity Inc. (0001603454) (Subject)

    11/14/24 4:26:12 PM ET
    $CELC
    Medical Specialities
    Health Care

    $CELC
    Financials

    Live finance-specific insights

    View All

    Celcuity to Hold Conference Call to Discuss Results for the PIK3CA Mutant Cohort of the Phase 3 VIKTORIA-1 Clinical Trial of Gedatolisib Regimens in HR+/HER- Advanced Breast Cancer on June 2, 2026

    MINNEAPOLIS, June 01, 2026 (GLOBE NEWSWIRE) -- Celcuity Inc. (NASDAQ:CELC), a clinical-stage biotechnology company focused on the development of targeted therapies for the treatment of multiple solid tumor indications, today announced it will host a conference call and live webcast to review results from the PIK3CA mutant cohort of the Phase 3 VIKTORIA-1 clinical trial on Tuesday, June 2, 2026 at 8:00 a.m. EDT / 7:00 a.m. CDT. Webcast and Conference Call Information The Celcuity management team will host a live webcast and conference call on Tuesday, June 2, 2026, at 8:00 a.m. EDT / 7:00 a.m. CDT to discuss the results from the Phase 3 VIKTORIA-1 trial. Those who would like to participat

    6/1/26 8:30:00 AM ET
    $CELC
    Medical Specialities
    Health Care

    Celcuity Inc. Reports Release of First Quarter 2026 Financial Results and Provides Corporate Update

     Phase 3 VIKTORIA-1 trial achieved primary endpoint with clinically meaningful improvement in progression-free survival in PIK3CA mutant cohort; detailed data for gedatolisib regimens will be presented at the 2026 ASCO Annual Meeting Phase 3 VIKTORIA-2 trial expanded to include a second study evaluating gedatolisib as first-line treatment in patients with endocrine-sensitive HR+/HER2- advanced breast cancerDevelopment of a gedatolisib formulation for subcutaneous injection underway; first patent application submitted to the U.S. Patent and Trademark OfficeManagement to host webcast and conference call today, May 14, 2026, at 4:30 p.m. EDT MINNEAPOLIS, May 14, 2026 (GLOBE NEWSWIRE) -- Celc

    5/14/26 4:01:00 PM ET
    $CELC
    Medical Specialities
    Health Care

    Celcuity Schedules Release of First Quarter 2026 Financial Results and Webcast/Conference Call

    MINNEAPOLIS, May 07, 2026 (GLOBE NEWSWIRE) -- Celcuity Inc. (NASDAQ:CELC), a clinical-stage biotechnology company pursuing development of targeted therapies for oncology, today announced that it will release its financial results for the first quarter 2026 after the market closes on Thursday, May 14, 2026. Management will host a webcast/teleconference the same day at 4:30 p.m. Eastern Time to discuss the results and provide a corporate update. Webcast and Conference Call Information To participate in the teleconference, domestic callers should dial 1-800-717-1738 and international callers should dial 1-646-307-1865. A live webcast presentation can also be accessed using this weblink: htt

    5/7/26 8:00:00 AM ET
    $CELC
    Medical Specialities
    Health Care